Global

Sep 09, 2016
Japanese pharma has voiced Brexit concerns, but it favored London as a European base well before the EMA opened its doors.
Sep 08, 2016
Pharmaceutical Executive
As the UK exits the European Union, pharma should prepare for changes by identifying key business issues, mitigating risks and creating plans for multiple scenarios.
Sep 07, 2016
Leela Barham reviews NHS England's proposals for the creation of Regional Medicines Optimization Committees.
Aug 15, 2016
Reflector outlines the obstacles ahead for Europe's revamped Innovative Medicines Initiative.
Aug 10, 2016
If managed access is to be a widely available option, it makes sense to re-assess just how much should be spent on it, writes Leela Barham.
Jul 29, 2016
A ‘new’ version of the English Cancer Drugs Fund (CDF) comes into force today. Leela Barham reports.
Jul 29, 2016
Paul Ranson examines how the UK biopharma must now adapt to a changing landscape.
Jul 27, 2016
Leela Barham looks at the EU plans for a European patent, and asks where the UK will fit in after Brexit.
Jul 20, 2016
Not yet, says Reflector. But to judge from the European Parliament's latest foray into the subject, there could be plenty of support for such an approach.
Jul 12, 2016
Pharmaceutical Executive
A look at how Europe’s new accelerated drug approval scheme can move existing review pathways to something better—and take a page from the FDA experience as well.
native1_300x100
lorem ipsum